What is an appropriate rapid, safe, and reversible management plan and documentation for a patient presenting with acute agitation?

Management of Acute Agitation

For undifferentiated acute agitation in the emergency department, use either a benzodiazepine (lorazepam 2-4 mg or midazolam) or a conventional antipsychotic (haloperidol 5 mg or droperidol) as first-line monotherapy, with droperidol preferred when rapid sedation is required. 1

Initial Approach: Verbal De-escalation First

Before reaching for medications, attempt verbal de-escalation techniques and environmental modifications. This should be your first-line intervention for all agitated patients, as it reduces the need for pharmacologic intervention, restraints, and associated complications 2, 3. However, when safety is immediately threatened or verbal techniques fail, proceed rapidly to pharmacologic management.

Critical Safety Assessment

Immediately rule out reversible medical causes before attributing agitation to psychiatric illness:

• Point-of-care glucose testing is mandatory - hypoglycemia can present as agitation and is rapidly reversible 3
• Consider anticholinergic or sympathomimetic toxicity - antipsychotics can worsen these conditions due to their anticholinergic properties 1
• Assess for hyperactive delirium, intoxication, or underlying medical illness 4
• Check vital signs - abnormal vitals suggest medical rather than primary psychiatric etiology

Common pitfall: Up to 46% of patients with apparent psychiatric agitation have underlying medical illness causing or exacerbating symptoms 1. Don't anchor on psychiatric diagnosis without medical clearance.

Pharmacologic Management Algorithm

For Undifferentiated Agitation (Unknown Etiology)

Level B Evidence Recommendations:

1. Benzodiazepine monotherapy:

   • Lorazepam 2-4 mg IM/IV, OR
   • Midazolam (weight-based dosing) 1

2. Conventional antipsychotic monotherapy:

   • Droperidol 5 mg IV (preferred for rapid sedation - works faster than haloperidol with shorter ED length of stay) 1
   • Haloperidol 5 mg IM (alternative if droperidol unavailable) 1

Critical caveat on droperidol: Despite FDA black box warning for QT prolongation, large case series (>12,000 patients) show no documented dysrhythmic events in patients without serious comorbidities 1. The evidence suggests droperidol is safer than the warning implies, but institutional policies may limit availability.

For Known Psychiatric Illness

Use antipsychotics (typical or atypical) as monotherapy for both agitation control and treatment of underlying condition 1:

• Ziprasidone 20 mg IM - rapid onset, well-tolerated, notably low incidence of extrapyramidal symptoms 1
• Olanzapine - effective with lower motor side effects 1
• Haloperidol 5 mg IM remains standard option 1

For Cooperative Patients Who Can Take Oral Medications

Combination therapy: Oral lorazepam 2 mg + oral risperidone shows similar efficacy to IM haloperidol/lorazepam combination 1

When Rapid Sedation is Essential

Level C Evidence: Combination of parenteral benzodiazepine + haloperidol may produce more rapid sedation than monotherapy 1

Special Population: Geriatric Patients (≥65 years)

AVOID midazolam in older adults - it poses excessive risk with 53% adverse event rate and 5.25-fold increased odds of adverse events compared to haloperidol 4. This is the most recent (2025) and highest-quality evidence specific to geriatric agitation.

Preferred agents for elderly:

• Quetiapine - only medication showing lower adverse event frequency (OR 0.27) compared to haloperidol 4
• Haloperidol remains acceptable alternative
• Lorazepam if benzodiazepine needed, but use cautiously

Geriatric-specific risks: Older adults have altered pharmacokinetics, increased sensitivity to adverse effects including respiratory depression, hypotension, dysrhythmia, and delirium exacerbation 4, 5.

Monitoring and Documentation

Document the following for each intervention:

• Sedation-Agitation Scale (SAS) scores before and after medication
• Specific indication (safety threat, inability to assess, etc.)
• Vital signs including QTc if using antipsychotics
• Response to treatment and any adverse effects
• Restraint use and duration if applicable

Documentation pitfall: Studies show complete documentation present in only 27.8% of agitation cases, with adverse effects documented in <7% 5. Thorough documentation is essential for quality improvement and medicolegal protection.

Adverse Effects to Monitor

• Benzodiazepines: Respiratory depression, paradoxical agitation, oversedation
• Haloperidol: Extrapyramidal symptoms, dystonia, QT prolongation
• Droperidol: QT prolongation (theoretical > actual risk), dystonia (rare)
• Ziprasidone: Minimal motor side effects, some QT prolongation
• All antipsychotics: Can worsen anticholinergic toxicity

When Initial Treatment Fails

If first medication ineffective:

• Reassess for missed medical causes
• Consider combination therapy if monotherapy used initially
• Repeat dosing may be needed (studies allowed repeated administration) 1
• Ketamine can be considered for extreme agitation refractory to standard agents 6

Restraints should be last resort after pharmacologic options exhausted, used only for immediate safety threats 2, 3.